," said Akash Patnaik, MD, Ph.D., MMSc, an accomplished physician-scientist and internationally-recognized expert in prostate cancer research and treatment, who is the senior author of the publication.
Patnaik's lab develops targeted therapeutic strategies to improve the responsiveness of prostate cancer to immunotherapy. They discovered that the They then tested a therapy regimen that consisted of three drugs targeting the PI3K, MEK, and Wnt/β-catenin signaling pathways. This brought the response rate to 100%.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »